KCNA3 and psoriasis: Remarkably, the administration of Stichodactyla helianthus neurotoxin (ShK), a well-known Kv1.3 blocker, demonstrated significant therapeutic benefits in psoriasiform skin grafts, suggesting Kv1.3 blockers as potentially novel therapeutic agents for psoriasis [39].